Physician profile
Mark M Davidson
NPI 1164459178
$14,278.53
in general payments reported to CMS, 2019-2025
38 companies · $2,277 in 2025
The $2,277 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,123 · 2020: $1,791 · 2021: $2,430 · 2022: $2,393 · 2023: $1,820 · 2024: $2,444 · 2025: $2,277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,411 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,410.66 |
| Education | $129.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $6,071.99 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $1,940.43 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Qol Medical, LLC | $1,547.71 | 2020-2025 | Sucraid, Sucraid |
| Abbvie INC. | $585.29 | 2019-2025 | Linzess, Viberzi |
| Genzyme Corporation | $563.94 | 2022-2025 | |
| Napo Pharmaceuticals INC | $548.92 | 2019-2023 | Mytesi |
| Capsovision, INC. | $316.76 | 2024-2025 | Capsocam Plus |
| Nestle Healthcare Nutrition INC. | $247.21 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $246.64 | 2019-2025 | Entyvio |
| Gilead Sciences, INC. | $243.70 | 2019-2023 | Epclusa |
| Redhill Biopharma INC. | $216.18 | 2020-2025 | Talicia, Movantik, Aemcolo |
| Romark Laboratories, Lc | $195.48 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $165.77 | 2022-2023 | |
| Concordia Pharmaceuticals INC. | $164.50 | 2019 | |
| Merck Sharp & Dohme LLC | $139.75 | 2020-2023 | Verquvo |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Davidson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.